匹多莫德辅助治疗婴幼儿反复呼吸道感染的疗效研究
|
摘要
目的:探究婴幼儿反复呼吸道感染在常规治疗治疗上加用匹多莫德辅助治疗对其免疫功能的影响。方法:选择2015年3月至2017年5月期间在郑州大学附属儿童医院治疗的76例反复呼吸道感染患儿作为研究对象,按随机数表法分成2组,各38例。对照组给予常规治疗,观察组在此基础上加用匹多莫德,比较两组临床疗效与治疗后免疫细胞及炎性介质水平。结果:观察组半年内感染次数少于对照组,且平均持续时间与抗生素使用时间均短于对照组,差异有统计学意义(P<0.05);观察组治疗后CD3+、CD4+、CD8+、IgG、IgA、IgM水平均较对照组高,PCT、TNF-α水平均较对照组低,IFN-γ、IL-4水平均较对照组高,差异有统计学意义(P<0.05)。结论:在常规治疗基础上辅助匹多莫德治疗婴幼儿反复呼吸道感染可降低机体炎症反应,提高免疫功能,减少感染次数,提高治疗效果。
Objective: To investigate the effect of the adjunctive therapy of pidomod on the immune function of infants with recurrent respiratory tract infection(RRTI). Methods: 76 children with recurrent respiratory tract infection who were treated in our hospital from March 2015 to May 2017 were randomly divided into two groups, with 38 cases in each group. The control group was treated with routine therapy, and the observation group was treated with pidomod on this basis. The clinical efficacy and the levels of immune cells and inflammatory mediators were compared between the two groups. Results: The frequency of infection in the observation group was less than that in the control group in half a year, and the mean duration and antibiotic use time were shorter than those in the control group(P<0.05). The levels of CD3+、CD4+、CD8+、Ig G、Ig A、Ig M in the observation group were higher than those in the control group(P<0.05), and the levels of TNF-α in the control group were lower than those in the control group(P<0.05). Conclusion: On the basis of routine treatment, the treatment of infantile recurrent respiratory tract infection with pidomod can reduce the inflammatory reaction, improve immune function, reduce the number of infections and improve the therapeutic effect.
Objective: To investigate the effect of the adjunctive therapy of pidomod on the immune function of infants with recurrent respiratory tract infection(RRTI). Methods: 76 children with recurrent respiratory tract infection who were treated in our hospital from March 2015 to May 2017 were randomly divided into two groups, with 38 cases in each group. The control group was treated with routine therapy, and the observation group was treated with pidomod on this basis. The clinical efficacy and the levels of immune cells and inflammatory mediators were compared between the two groups. Results: The frequency of infection in the observation group was less than that in the control group in half a year, and the mean duration and antibiotic use time were shorter than those in the control group(P<0.05). The levels of CD3+、CD4+、CD8+、Ig G、Ig A、Ig M in the observation group were higher than those in the control group(P<0.05), and the levels of TNF-α in the control group were lower than those in the control group(P<0.05). Conclusion: On the basis of routine treatment, the treatment of infantile recurrent respiratory tract infection with pidomod can reduce the inflammatory reaction, improve immune function, reduce the number of infections and improve the therapeutic effect.
引文
[1]李素芳,来庆和,袁永红,等.学龄前儿童反复呼吸道感染状态及其高危因素分析[J].实用预防医学,2016,23(10):1232-1233.
[2]王桂玲,王媛媛,杨征.江苏省宿迁市儿童反复呼吸道感染相关因素及治疗现状分析[J].中国医药,2015,10(6):804-808.
[3]中华医学会儿科学分会呼吸学组,《中华儿科杂志》编辑委员会.反复呼吸道感染的临床概念和处理原则[J].中华儿科杂志,2008,46(2):108-110.
[4]杨华英,张良,廖骏华.婴幼儿支原体肺炎后反复发作性呼吸道感染因素分析[J].临床肺科杂志,2016,21(5):822-824.
[5]何玲,王松,符宗敏,等.儿童肺炎支原体肺炎后发生反复呼吸道感染的多因素分析[J].临床儿科杂志,2015,33(2):117-120.
[6]吴佩琼,侯俏珍,黄俪锋,等.儿童反复呼吸道感染部分相关影响因素分析[J].国际儿科学杂志,2015,42(4):450-453.
[7]鲁红春.匹多莫德联合常规药物治疗对反复呼吸道感染儿童感染状态、免疫功能的影响[J].海南医学院学报,2017,23(19):2708-2711.
[8]马力忠,王桂兰,梁桂明,等.免疫调节剂对小儿反复呼吸道感染临床症状及免疫功能的影响[J].中国妇幼保健,2016,31(2):414-415.
[9]吴烈霞.匹多莫德口服液在儿童反复呼吸道感染中的应用[J].中国医师进修杂志,2015,38(6):394-397.
[10]王晔华.匹多莫德治疗和预防儿童反复呼吸道感染发作42例[J].中国药业,2014,23(11):144-145.
[11]潘筱.学龄前反复呼吸道感染儿童维生素A水平与免疫功能变化研究[J].中国妇幼保健,2015,30(35):6241-6243.
[12]丁树和.免疫球蛋白G亚型检测在小儿反复呼吸道感染中的应用[J].中国实验诊断学,2017,21(5):872-873.
[13]张云,张晓,范徐威.匹多莫德口服液联合斯奇康治疗小儿反复呼吸道感染的临床疗效研究[J].临床和实验医学杂志,2015,14(18):1541-1543.
[14]俞秀英,王玲玲,徐昌平.匹多莫德辅助治疗患儿反复呼吸道感染的疗效分析[J].中华医院感染学杂志,2014,24(17):4361-4362,4370.
[15]由军,许小红,范慧子,等.匹多莫德对反复呼吸道感染患儿外周血T淋巴细胞亚群变化的影响及其临床疗效[J].现代生物医学进展,2014,14(28):5499-5502.
[2]王桂玲,王媛媛,杨征.江苏省宿迁市儿童反复呼吸道感染相关因素及治疗现状分析[J].中国医药,2015,10(6):804-808.
[3]中华医学会儿科学分会呼吸学组,《中华儿科杂志》编辑委员会.反复呼吸道感染的临床概念和处理原则[J].中华儿科杂志,2008,46(2):108-110.
[4]杨华英,张良,廖骏华.婴幼儿支原体肺炎后反复发作性呼吸道感染因素分析[J].临床肺科杂志,2016,21(5):822-824.
[5]何玲,王松,符宗敏,等.儿童肺炎支原体肺炎后发生反复呼吸道感染的多因素分析[J].临床儿科杂志,2015,33(2):117-120.
[6]吴佩琼,侯俏珍,黄俪锋,等.儿童反复呼吸道感染部分相关影响因素分析[J].国际儿科学杂志,2015,42(4):450-453.
[7]鲁红春.匹多莫德联合常规药物治疗对反复呼吸道感染儿童感染状态、免疫功能的影响[J].海南医学院学报,2017,23(19):2708-2711.
[8]马力忠,王桂兰,梁桂明,等.免疫调节剂对小儿反复呼吸道感染临床症状及免疫功能的影响[J].中国妇幼保健,2016,31(2):414-415.
[9]吴烈霞.匹多莫德口服液在儿童反复呼吸道感染中的应用[J].中国医师进修杂志,2015,38(6):394-397.
[10]王晔华.匹多莫德治疗和预防儿童反复呼吸道感染发作42例[J].中国药业,2014,23(11):144-145.
[11]潘筱.学龄前反复呼吸道感染儿童维生素A水平与免疫功能变化研究[J].中国妇幼保健,2015,30(35):6241-6243.
[12]丁树和.免疫球蛋白G亚型检测在小儿反复呼吸道感染中的应用[J].中国实验诊断学,2017,21(5):872-873.
[13]张云,张晓,范徐威.匹多莫德口服液联合斯奇康治疗小儿反复呼吸道感染的临床疗效研究[J].临床和实验医学杂志,2015,14(18):1541-1543.
[14]俞秀英,王玲玲,徐昌平.匹多莫德辅助治疗患儿反复呼吸道感染的疗效分析[J].中华医院感染学杂志,2014,24(17):4361-4362,4370.
[15]由军,许小红,范慧子,等.匹多莫德对反复呼吸道感染患儿外周血T淋巴细胞亚群变化的影响及其临床疗效[J].现代生物医学进展,2014,14(28):5499-5502.